Akero Therapeutics (AKRO) stock surged 5.95% in intraday trading on Wednesday, buoyed by the company's successful equity raise and positive clinical trial results for its lead drug candidate.
On Tuesday, Akero Therapeutics announced the pricing of an upsized public offering, raising $350 million through the sale of approximately 5.3 million shares and pre-funded warrants to purchase an additional 2 million shares. The offering was well-received by investors, signaling confidence in the company's financial position and growth prospects.
Moreover, the stock's rally was further fueled by promising results from a study on Akero's lead drug candidate, efruxifermin. The drug demonstrated its ability to reverse scarring and improve liver health in patients with a type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis (MASH). This positive development highlighted the potential of efruxifermin and bolstered investor optimism in the company's pipeline.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。